Fikrettin ŞAHİN, Tuğçe ÖZYAZICI, Meriç KÖKSAL

Synthesis, spectral characterization, and biological studies of 3,5-disubstituted1,3,4-oxadiazole-2(3H)-thione derivatives

The reaction of 3,4-dichlorophenyl-1,3,4-oxadiazole-2(3H)-thione with piperidine derivatives via Mannich reaction was used to generate eleven novel compounds in moderate to good yields. Synthesized molecules were characterized according to their structure with $^{1} H NMR,^ {13}C NMR$ and FT-IR spectral foundations, which were compatible with literature informations. Antimicrobial activity and cytotoxicity studies were done by disc diffusion and NCI-60 sulphordamine B assay methods. The antimicrobial test results revealed that synthesized compounds have better activity against gram-positive species than gram-negative ones. A total analysis of the antibacterial, antifungal, and antiyeast activity revealed that newly synthesized compounds were really active against Bacillus cereus, Bacillus ehimensis, and Bacillus thuringiensis species. For cytotoxicity, among three different cancer cell lines (HCT116, MCF7, HUH7) compounds 5c, 5d, 5e, 5f, 5g, 5i, 5j and 5k were seemed especially effective on HUH7 cancer cell line via moderate to good activity. More significantly, against liver carcinoma cell line (HUH7) most of the compounds of the series (5c-5g and 5i-5j) have better $IC_{50}$ values $(IC_{50}= 18.78 µM)$ than 5-Florouracil (5-FU) and also compound 5d possessed 10.1 µM value, which represents good druggable cytotoxic activity. Further, the molecules were also screened for in silico chemoinformatic and toxicity data to gather the predicted bioavailibity and safety measurements.

PDF

___

1. Penesyan A, Gillings M, Paulsen IT. Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities. Molecules 2015; 20 (4): 5286-5298.
2. Tetz G, Tetz V. In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria. Antimicrobial Resistance and Infection Control 2015; 4: 45. Doi: 10.1186/s13756-015-0088-x
3. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and Moleculer Biology Reviews 2010; 74(3): 417-433. Doi: 10.1128/MMBR.00016-10
4. Pitta E, Tsolaki E, Geronikaki A, Petrović J, Glamočlija J et al. 4-Thiazolidinone derivatives as potent antimicrobial agents: microwaveassisted synthesis, biological evaluation and docking studies. Medicinal Chemistry Communications 2015; 6 (2): 319. Doi: 10.1039/ c4md00399c.
5. Critically important antimicrobials for human medicine, 6th revision. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
6. Baguley BC. Multiple drug resistance mechanisms in Cancer. Molecular Biotechnology 2010; 46: 308-316. Doi: 10.1007/s12033-010-9321-2
7. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. International Journal of Antimicrobial Agents 2012; 39: 295-299. Doi: 10.1016/j.ijantimicag.2011.12.006
8. Mandell LA, Ball P, Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clinical Infectious Diseases 2001; 32: 72-79. Doi: 10.1086/319379
9. Lincke CR, Bliek AM, Schuurhuis GJ, Velde-Koerts T, Smit JJ et al. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Research 1990; 50: 1779-1785. PMID: 1968359
10. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st Century — a clinical super-challenge. The New England Journal of Medicine 2019; 360: 439-443. Doi: 10.1056/NEJMp0804651
11. Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT. Cancer therapeutics-opportunities, challenges and advances in drug delivery. Journal of Applied Pharmaceutical Science 2011; 1: 1–10.
12. Felício MR, Silva ON, Gonçalves S, Santos NC, Franco OL. Peptides with dual antimicrobial and anticancer activities. A Review. Frontiers in Chemistry 2017; 5 (5). Doi: 10.3389/fchem.2017.00005
13. Alibek K, Bekmurzayeva A, Mussabekova A, Sultankulov B. Using antimicrobial adjuvant theraphy in cancer treatment: a review. Infectious Agents and Cancer 2012; 7: 33. Doi: 10.1186/1750-9378-7-3
14. Otova B, Hrdy J, Votruba I, Holy A. In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates pmedap and pmeg. Anticancer Research 2009; 29: 1295-1302. PMID: 19414378
15. Mondello C, Scovassi AI. Telomeres, telomerase, and apoptosis. Biochemistry and cell biology-biochimie et biologie cellulaire 2004; 82 (4): 498-507. Doi: 10.1139/o04-048.
16. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-allylamino-17-demethoxygeldanamycin (17-aag) is effective in down-regulating mutated, constitutively activated kit protein in human mast cells. Blood 2004; 103 (3): 1078-1084. Doi: 10.1182/blood-2003-07-2477
17. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K et al. Targeting hsp90 for cancer therapy. British Journal of Cancer 2009; 100(10): 1523-9. Doi: 10.1038/sj.bjc.6605066
18. Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N et al. Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Free Radical Biology and Medicine 2009; 46(2): 232-7. Doi: 10.1016/j.freeradbiomed.2008.10.023
19. Ding WQ, Liu BL, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Research 2005; 65(8): 3389. Doi: 10.1158/0008-5472.CAN-04-3577.
20. Hye JJ, Yonghyo K, Hyang BL, Ho JK. Antiangiogenic Activity of the Lipophilic Antimicrobial Peptides from an Endophytic Bacterial Strain Isolated from Red Pepper Leaf. Molecules and Cells 2004; 38(3): 273–8. Doi: 10.14348/molcells.2015.2320
21. Curiel TJ. Tregs and rethinking cancer immunotherapy. Journal of Clinical Investigation 2007; 117: 1167–74. Doi: 10.1172/JCI31202
22. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N et al. Molecular targeting of the oncogene eif4e in acute myeloid leukemia (aml): A proof-of-principle clinical trial with ribavirin. Blood 2009; 114(2): 257-60. Doi: 10.1182/blood-2009-02-205153
23. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB. Ribavirin suppresses eif4e-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mrna cap. Proceedings of the National Academy of Sciences (Proceedings of the National Academy of Sciences of the United States of America) 2004; 101(52): 18105-10. Doi: 10.1073/pnas.040692710210.1073/pnas.0406927102
24. Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB et al. Thiazole antibiotics against breast cancer. Cell Cycle 2010; 9(6): 1214-17. Doi: 10.4161/cc.9.6.10955
25. Boström J, Hogner A, Llinas A, Wellner E, Plowright AT. Oxadiazoles in Medicinal Chemistry. Journal of Medicinal Chemistry 2012; 55(5): 1817-30. Doi: 10.1021/jm2013248
26. Du Q, Li D, Pi Y, Li J, Sun J et al. Novel 1,3,4-oxadizole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents. Bioorganic Medicinal Chemistry 2013; 21: 2286-97. Doi: 10.1016/j.bmc.2013.02.008
27. Ahsan MJ, Sharma J, Bhatia S, Goyal PK, Shank-hala K et al. Synthesis of 2,5-disubstituted-1,3,5-oxadiazole analogs as novel anticancer and antimicrobial agents. Letters of Drug Design and Discovery 2014; 11: 413. Doi: 10.2174/157018 0810666131113211647
28. Savariz FC, Formagio ASN, Barbosa VA, Foglio MA, Carvalho JE et al. Synthesis, antitumor and antimicrobial activity of novel 1-substitutedphenyl-3-[3-alkylamino(methyl)-2-thioxo-1,3,4-oxadiazol-5-yl]b-carboline derivatives. Journal of Brazilian Chemical Society 2010; 21(2): 288-98. Doi: 10.1590/S0103-50532010000200014
29. Selvaraj K, Kulanthai K, Sadhasivam G. Synthesis, characterization and biological evaluation of novel 2,5-disubstituted-1,3,4-oxadiazole derivatives. Saudi Pharmaceutical Journal 2017; 25: 337-45. Doi: 10.1016/j.jsps.2016.07.004
30. Koksal M, Bilge SS, Bozkurt A, Sahin S, Isik S et al. Synthesis, characterization and anti-inflammatory activity of new 5-(3,4-dichlorophenyl)- 2-(aroylmethyl)thio-1,3,4-oxadiazoles. Arzneimittel-Forschung 2008; 58: 510-4. Doi: 10.1055/s-0031-1296550
31. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolke RH. Manual of Clinical Microbiology ASM. Washington DC: 6, 1995, pp. 1482 32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J et al. New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of National Cancer Institute 1990; 82(13): 1107-1112. Doi: 10.1093/jnci/82.13.1107
33. Glück J, Buhrke T, Frenzel F, Braeuning A, Lampen A. In silico genotoxicity and carcinogenicity prediction for food-relevant secondary plant metabolites. Food and Chemical Toxicology 2018; 116: 298-306. Doi: 10.1016/j.fct.2018.04.024
34. Sowjanya C, RamaBharathi V, Kalpana Devi G, Rajitha G. Synthesis and evaluation of some novel 3-[5-phenyl-1,3,4-oxadiazole-2-yl]-2- (substitutedstyryl)-quinazoline-4(3H)-ones for antibacterial activity. Journal of Chemical and Pharmaceutical Research 2011; 3(6): 212-6
35. Romano E, Soria NAJ, Rudyk R, Silvia A. Brandán. Theoretical study of the infrared spectrum of 5-phenyl-1,3,4-oxadiazole-2-thiol by using DFT calculations. Molecular Simulation 2012; 38(7): 561–6. Doi: 10.1080/08927022.2011.640936
36. Parikh K, Joshi D. Synthesis and evaluation of 2-(5-(aryl)-1,3,4-oxadiazol-2-ylthio)-N-(3-(trifluoromethyl)phenyl)acetamides and N-(4- chloro-3-fluorophenyl)-2-(5-(aryl)-1,3,4-oxadiazol-2-ylthio)acetamides as antimicrobial agents. Journal of Chemical Sciences 2014; 126(3): 827–35. Doi: 10.1007/s12039-014-0625-9
37. Sankhe NM, Durgashivaprasad E, Kutty NG, Rao JV, Narayanan K et al. Novel 2,5-disubstituted-1,3,4-oxadiazole derivatives induce apoptosis in HepG2 cells through p53 mediated intrinsic pathway. Arabian Journal of Chemistry 2019; 12, 2548–55. Doi: 10.1016/j. arabjc.2015.04.030
38. Chikhalia KH, Vashi DB, Patel MJ. Synthesis of a novel class of some 1,3,4-oxadiazole derivatives as antimicrobial agents. Journal of Enzyme Inhibition and Medicinal Chemistry 2009; 24(3): 617-22. Doi: 10.1080/14756360802318936
39. Modh RP, Shah D, Chikhalia KH. 2-(Quinolin-4-ylthio)-1,3,4-oxadiazole derivatives: Design, synthesis, antibacterial and antifungal studies. Indian Journal of Chemistry 2013; 52B: 1318-24.
40. Jadhav BP, Yadav AR, Gore MG. Concept of drug likeness in pharmaceutical research. International. Journal of Pharma and Bio Sciences. 2015; 6: 142-54.
41. Bakht MA, Yar MS, Abdel-Hamid SG, Al-Qasoumi SI, Samad A. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. European Journal of Medicinal Chemistry. 2010; 45: 5862-69. Doi: 10.1016/j.ejmech.2010.07.069
42. Tian S, Wang J, Li Y, Li D, Xu L et al. The application of in silico drug-likeness predictions in pharmaceutical research. Advanced Drug Delivery Reviews. 2015; 86: 2-10. Doi: 10.1016/j.addr.2015.01.009
43. Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery. ACS Chemical Neuroscience. 2013; 3: 50-68. Doi: 10.1021/cn200100h
44. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW et al. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry. 2002; 45(12): 2615-23 Doi: 10.1021/jm020017n